

Oncoshot inks MoU With Singapore Clinical Research Institute

15 April 2022 | News

Through this partnership, SCRI now offers investigators access to aggregated hospital-approved insights based on anonymised, well-annotated, and up-to-date patient data from across Oncoshot's network of cancer institutes

Oncoshot has signed a memorandum of understanding (MoU) with the Singapore Clinical Research Institute (SCRI), the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS).

This collaboration comes under Project EISE (Enhanced Clinical Trial Initiation, Screening and Enrolment; pronounced 'easy') to address two key challenges. Firstly, public healthcare institution (PHI) clinical trial investigators wishing to conduct trials on promising cancer treatments are often limited to the patient pool of their affiliated cancer institutes which may be insufficient. These investigators may not know which other cancer centres to approach for more patients.

Through SCRI, PHI investigators can now request access to anonymised, aggregated information regarding the oncology patient populations in Oncoshot's network of public and private healthcare institutes.

Secondly, the process of conducting feasibilities and subsequently screening and enrolling patients for cancer clinical trials is presently lengthy, cumbersome, and manual. This collaboration provides clinical trial investigators with a platform to identify patients in a semi-automated manner when leveraging Oncoshot's trial matching artificial intelligence (AI) platform. The platform provides investigators with a new capability to perform detailed reviews of individual de-identified patient records to determine if they match highly specific trial criteria. The local institutes' patient databases may also be further enriched with biomarker data to allow trial investigators to improve their chances of identifying suitable patients for these studies.